MedTrace Logo

A Study of Optical Imaging With Light From Radiotracers in Cancer Patients

NCT03484884 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2026-04-28

No results posted yet for this study

Summary

The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.

Conditions

Interventions

DIAGNOSTIC_TEST

Cerenkov luminescence imaging.

Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.

Sponsors & Collaborators

Principal Investigators

  • Jan Grimm, MD, PhD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-20
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03484884 on ClinicalTrials.gov